Highlights
- •This study shows that there were risks for new-onset diabetes mellitus (NODM) in statin users.
- •There was higher risk for NODM in statin low-users than high-users.
- •There was a possibility of dose and type differences in statin’s diabetogenic effects.
Abstract
Aim
We investigated the association between statin use and new-onset diabetes (NODM) in
Korean adults with hypercholesterolemia.
Methods
This study performed based on data from the National Health Insurance Service-National
Health Screening Cohort for the years from 2002 to 2015. Statin users classified as
high- or low- users according to medication possession ratio. Statin non-users consisted
of hypercholesterolemic participants who never used statin over the entire follow-up
period. 21,469 participants (10,880 statin users, 10,589 statin non-users) with a
median follow-up period of 12.5 years were included. We estimated the NODM risk based
on the survival analyses. In particular, to adjust for confounding effects, we considered
Cox proportional hazards regression models over three stages.
Results
Compared to non-users, statin users had a significantly higher risk for NODM. The
fully adjusted hazard ratios (aHRs) (95% confidential intervals [95% CIs]) of statin
users for NODM were 1.43 (1.31–1.57) in men, and 1.86 (1.66–2.10) in women, respectively
after adjusted confounding factors including age and lifestyle factors. Compared to
high-users, aHRs (95% CIs) of low-users for NODM were 1.16 (1.03–1.30) and 1.28 (1.16–1.43)
in men and women, respectively.
Conclusions
In hypercholesterolemic patients, statin users have a higher risk of NODM than non-users.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Primary Care DiabetesAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Non-communicable diseases in the Asia-Pacific region: prevalence, risk factors and community-based prevention.Int. J. Occup. Med. Environ. Health. 2015; : 1-7
- IDF Diabetes Atlas: global estimates of diabetes prevalence for 2017 and projections for 2045.Diabetes Res. Clin. Pract. 2018; 138: 271-281
- The Ministry of Health and Welfare and the Korean Centers for Disease Control and Prevention, Current Status and Issues of Chronic Disease.2018 ((Available from : file:)
- Global healthcare expenditure on diabetes for 2010 and 2030.Diabetes Res. Clin. Pract. 2010; 87: 293-301
- Medical care expenditures for diabetes, its chronic complications, and its comorbidities.Prev. Med. 1999; 29: 173-186
- Statins: mechanism of action and effects.J. Cell. Mol. Med. 2001; 5: 378-387
- 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.J. Am. Coll. Cardiol. 2014; 63: 2889-2934
- Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.JAMA. 2011; 305: 2556-2564
- Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials.Lancet. 2010; 375: 735-742
- Clinical significance of diabetes likely induced by statins: evidence from a large population-based cohort.Diabetes Res. Clin. Pract. 2017; 133: 60-68
- Statin therapy and risk of developing type 2 diabetes: a meta-analysis.Diabetes Care. 2009; 32: 1924-1929
- FDA Drug Safety Communication: Important Safety Label Changes to Cholesterol-lowering Statin Drugs.US Food and Drug Administration, Rockville, MD2012 (Available from https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs)
- Medication possession ratio: implications of using fixed and variable observation periods in assessing adherence with disease-modifying drugs in patients with multiple sclerosis.Patient Prefer. Adherence. 2013; 7: 509
- Statins and multiple noncardiovascular outcomes: umbrella review of meta-analyses of observational studies and randomized controlled trials.Ann. Intern. Med. 2018; 169: 543-553
- Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors.Arch. Neurol. 2000; 57: 1439-1443
- Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease.J. Am. Soc. Nephrol. 2003; 14: 1605-1613
- Statins and glycaemic control in individuals with diabetes: a systematic review and meta-analysis.Diabetologia. 2014; 57: 2444-2452
- Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial.Lancet. 2012; 380: 565-571
- Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study.Circulation. 2001; 103: 357-362
- Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial.Diabetes Care. 2003; 26: 2713-2721
- Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus.Am. J. Cardiol. 2013; 111: 1123-1130
- Statins and new-onset diabetes: a retrospective longitudinal cohort study.Clin. Ther. 2012; 34: 1977-1983
- Statin and the risk of new-onset diabetes mellitus.J. Korean Med. Assoc. 2017; 60: 901-911
- Risk of diabetes in patients treated with HMG-CoA reductase inhibitors.Metab.-Clin. Exp. 2015; 64: 482-488
- Impact of statin use on development of new-onset diabetes mellitus in Asian population.Am. J. Cardiol. 2016; 117: 382-387
- Impact of statins on risk of new onset diabetes mellitus: a population-based cohort study using the Korean National Health Insurance claims database.Ther. Clin. Risk Manage. 2016; 12: 1533
- Statin treatment and new-onset diabetes: a review of proposed mechanisms.Metabo.-Clin. Exp. 2014; 63: 735-745
- Effects of simvastatin on glucose metabolism in mouse MIN6 cells.J. Diabetes Res. 2014; 2014https://doi.org/10.1155/2014/376570
- Inhibition by simvastatin, but not pravastatin, of glucose‐induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L‐type Ca2+ channels in rat islet β‐cells.Br. J. Pharmacol. 1999; 126: 1205-1213
- Reduction of serum ubiquinol-10 and ubiquinone-10 levels by atorvastatin in hypercholesterolemic patients.J. Atheroscler. Thromb. 2005; 12: 111-119
- Statin-induced diabetes: perhaps, it’s the tip of the iceberg.QJM. 2010; 104: 174-178
- Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin.Biol. Pharm. Bull. 2003; 26: 1681-1684
- Methods for evaluation of medication adherence and persistence using automated databases.Pharmacoepidemiol. Drug Saf. 2006; 15: 565-574
- Relationship between adherence level to statins, clinical issues and health‐care costs in real‐life clinical setting.Value Health. 2010; 13: 87-94
Article info
Publication history
Published online: September 20, 2019
Accepted:
August 28,
2019
Received in revised form:
August 17,
2019
Received:
May 31,
2019
Identification
Copyright
© 2019 Primary Care Diabetes Europe. Published by Elsevier Ltd. All rights reserved.
